# LCI-HEM-MYE-CRD-002: Carfilzomib-Revlimid-Dexamethasone-Elotuzumab in Relapsed/Refractory Multiple Myeloma

> **NCT03361306** · PHASE2 · COMPLETED · sponsor: **Wake Forest University Health Sciences** · enrollment: 15 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** Elotuzumab

## Key facts

- **NCT ID:** NCT03361306
- **Lead sponsor:** Wake Forest University Health Sciences
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-01-09
- **Primary completion:** 2021-06-04
- **Final completion:** 2025-02-14
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2026-03-06

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03361306

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03361306, "LCI-HEM-MYE-CRD-002: Carfilzomib-Revlimid-Dexamethasone-Elotuzumab in Relapsed/Refractory Multiple Myeloma". Retrieved via AI Analytics 2026-07-08 from https://api.ai-analytics.org/clinical/NCT03361306. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*